{name}
{subtitle}
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~5 mi. (Vicenza, Italy, +163 more cities)
facility
AULSS8 Berica-Ospedale S.Bortolo-ONCOLOGIA CLINICA ( Site 0562)
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH
city
~29 mi. (Padova, Italy, +122 more cities)
facility
Istituto Oncologico Veneto IRCCS (IOV)
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~29 mi. (Padova, Italy, +93 more cities)
facility
Istituto Oncologico Veneto IRCCS-Oncologia Medica 1 ( Site 0600)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
city
~29 mi. (Padova, Italy, +262 more cities)
facility
IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +2 more drugs
drug type
hormone therapy, +1 more type
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
city
~29 mi. (Padova, Italy, +260 more cities)
facility
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda
biomarker
ERBB2 Amplification, +1 more biomarker
drug type
immunotherapy, +1 more type
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
city
~29 mi. (Padova, Italy, +81 more cities)
facility
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda
drug
atezolizumab, +2 more drugs
drug type
immunotherapy, +1 more type
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
city
~29 mi. (Padova, Italy, +179 more cities)
facility
Istituto Oncologico Veneto IRCCS
drug
atezolizumab, +1 more drug